EP0973528A2 - Composition therapeutique, procede de preparation de la composition et utilisation de cette derniere pour traiter des infections virales chez l'homme - Google Patents

Composition therapeutique, procede de preparation de la composition et utilisation de cette derniere pour traiter des infections virales chez l'homme

Info

Publication number
EP0973528A2
EP0973528A2 EP98919433A EP98919433A EP0973528A2 EP 0973528 A2 EP0973528 A2 EP 0973528A2 EP 98919433 A EP98919433 A EP 98919433A EP 98919433 A EP98919433 A EP 98919433A EP 0973528 A2 EP0973528 A2 EP 0973528A2
Authority
EP
European Patent Office
Prior art keywords
milliliters
grams
treatment regimen
treatment
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98919433A
Other languages
German (de)
English (en)
Inventor
Travis Benkendorfer
Edward Sopcack
Arthur D. Ericsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viron Corp
Original Assignee
Viron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viron Corp filed Critical Viron Corp
Publication of EP0973528A2 publication Critical patent/EP0973528A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof

Definitions

  • This invention relates to a therapeutic composition that can be used to treat human viral infections .
  • This invention also relates to a method of making this therapeutic composition and a protocol for the clinical treatment of viral infections, generally, and human immunodeficiency virus (HIV) infections, specifically.
  • HIV human immunodeficiency virus
  • HIV-1 remains the infective strain seen in most of the world, variants have recently appeared.
  • the most significant variant to appear is HIV-2, which was isolated from AIDS patients in West Africa in 1986.
  • the proteins encoded by HIV-2 are only about 40% homologous to proteins encoded by the original HIV isolates.
  • Dual infection with HIV-1 and HIV-2 is associated with over 63% of the AIDS cases in the Ivory Coast. AIDS patients with this dual infection generally have a life expectancy of less than one year, resulting from the effects of the infection itself and the susceptibility to opportunistic infections, Kaposi's sarcoma, malnutrition, and persistent diarrhea.
  • a treatment which is effective in delaying, controlling, or reversing the course of AIDS in individuals having combined HIV-1 and HIV-2 infections would be very desirable.
  • An effective treatment for individuals having combined HIV-1 and HIV-2 infections would prolong their drastically shortened life, thus allowing further treatment of the HIV infection itself and its associated conditions.
  • An effective treatment for individuals having combined HIV-1 and HIV-2 infections could also result in the deadly dual infection epidemic being eradicated or at least confined to its present locations .
  • a treatment which is effective in converting a clinically significant portion of patients who are positive for HIV-1 and HIV-2 to those with a negative status would be a substantial step in finding a cure for AIDS .
  • VIRON a composition of matter having anti-viral properties that is designated VIRON.
  • VIRON comprises a mixture of chemicals combined in a specific manner that is further combined with germanium sesquioxide, and is optionally used in combination with oc-interferon.
  • VIRON a protocol for the use of VIRON alone or in combination with nutritional supplements is disclosed as a clinical treatment for viral infections, generally, and HIV infections, specifically.
  • VIRON and nutritional supplements the inventors have discovered a new and useful HIV treatment method that statistically increased CD4+ lymphocyte levels in patients infected with HIV in Africa. Using these methods, they have developed an effective treatment for individuals infected by both HIV-1 and HIV-2, thus overcoming the difficulties seen in the prior art. These methods have the potential to lead to improved treatment of AIDS patients and a cure for this disease.
  • This invention relates to a VIRON base material comprising a mixture of inositol oxidized with nitric acid whose pH is increased by using sodium hydroxide to which sodium sulfite, pyrocatechol, and copper sulfate are then added after dilution with distilled water and heating. Germanium sesquioxide is then added in varying amounts to the VIRON base material solution in preparation for patient treatment .
  • a combination of VIRON base material/germanium sesquioxide solution and, optionally, ⁇ -interferon are
  • compositions of this invention as well as their method of production and use in clinical treatment are further illustrated in detail by the following examples.
  • Example 1 Preparation of the VIRON Base Material
  • the VIRON base material is produced by oxidizing about 1 kilogram of inositol with concentrated nitric acid. This reaction should be run to completion which is indicated by the formation of a dark brown material . At room temperature, this reaction is allowed to proceed for about two days. Alternatively, the reaction can be performed in about 15 minutes at a temperature of about 290 degrees Fahrenheit. The resulting solution is heated to about 212 degrees Fahrenheit and kept at this temperature for about one hour. While at this temperature, the pH of this solution is changed to about 4.0 by adding potassium hydroxide. After the' addition of the potassium hydroxide, the solution is allowed to return to room temperature.
  • the resulting solution is then diluted into about 7500 miHiliters of distilled water in a stainless steel container and the diluted solution is heated to a temperature of about 212 degrees Fahrenheit. While the solution is at this temperature, about 3 pounds of sodium sulfite are added. Once the sodium sulfite has dissolved and while the solution is still hot, about 330 grams of pyrocatechol are added to the solution. Once the pyrocatechol has dissolved and while the solution is still hot, about 7 grams of copper sulfate are added to the solution and dissolved. While the solution is still hot, it is diluted up to about 4 gallons in total with distilled water and the solution is allowed to cool to room temperature.
  • the first week of treatment about 1.5 milliliters of a solution containing about 5 grams of germanium sesquioxide per 200 milliliters of the VIRON base material solution are given to each patient under the tongue four times daily.
  • the second week of treatment about 1.5 milliliters of a solution containing about 10 grams of germanium sesquioxide per 200 milliliters of the VIRON base material solution are given to each patient under the tongue four times daily.
  • the third week of treatment about 1.5 milliliters of a solution containing about 12 grams of germanium sesquioxide per 200 milliliters of the VIRON base material solution are given to each patient under the tongue four times daily.
  • interferon at a strength of 200 International Units (IU) is given orally to each patient five times daily for the first week.
  • IU International Units
  • tablets used are Alferon.
  • liquid -interferon which is manufactured
  • 200 IU is given orally to each patient three times daily. From this point onward in the treatment regimen, 1 tablet of ⁇ -interferon at a strength of 200 I.U. is
  • nutritional supplements supplied by Reliv, Inc. of Chesterfield, Missouri are given during the entire treatment regimen.
  • Patients use the Reliv Classic nutritional supplement first.
  • This supplement contains a mixture of proteins, herbs, and other nutritional supplements, including ⁇ -carotene, that is manufactured by Reliv, Inc. under a license from _he owner of U.S. Patent No. 4,737,364.
  • the patients add 1 scoop of this supplement from a container to one-half liter of water and drink 3 one-half liters of this mixture per day. Due to the lack of availability of safe drinking water in sub- Saharan Africa, patients residing in this geographical area are instructed to use bottled water or boiled water. If they use the latter, they are instructed to allow it to cool before mixing in this supplement. They are also instructed to store the mixture in a cool place.
  • One container of this nutritional supplement lasts between two and three weeks .
  • This nutritional supplement contains a mixture of vitamins and minerals.
  • This nutritional supplement is the subject of a pending patent application. As above, the patients add 1 scoop of supplement from a container to one-half liter of water and drink 3 one-half liters of this mixture per day. Again, if they reside in sub-Saharan Africa, they are instructed to use bottled water or boiled water. If they use the latter, they are instructed to allow it to cool before mixing in this supplement. They are also instructed to store the mixture in a cool place. One container of this nutritional supplement lasts between two and three weeks .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne une matière de base ayant des propriétés antivirales qui comprend un mélange d'inositol oxydé avec de l'acide nitrique dont on a augmenté le pH avec de l'hydroxyde de sodium auquel on a ajouté ensuite du sulfite de sodium, du pyrocatéchol et du sulfate de cuivre après dilution avec de l'eau distillée et chauffage. On peut ensuite ajouter à la matière de base du sesquioxyde de germanium dans des quantiés variables pour préparer un traitement adapté au patient. On utilise une combinaison de solution de sesquioxyde de germanium/matière de base et facultativement un alpha-interféron dans un régime clinique spécifique utilisé dans le traitement de personnes contaminées par le VIH. Dans une forme d'exécution préférée ce traitmenent est combiné avec l'utilisation de suppléments nutritionnels par les personnes contaminées.
EP98919433A 1997-04-09 1998-04-09 Composition therapeutique, procede de preparation de la composition et utilisation de cette derniere pour traiter des infections virales chez l'homme Withdrawn EP0973528A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US826368 1992-01-27
US82637197A 1997-04-09 1997-04-09
US82636897A 1997-04-09 1997-04-09
PCT/IB1998/000818 WO1998044935A2 (fr) 1997-04-09 1998-04-09 Composition therapeutique, procede de preparation de la composition et utilisation de cette derniere pour traiter des infections virales chez l'homme
US826371 2001-04-04

Publications (1)

Publication Number Publication Date
EP0973528A2 true EP0973528A2 (fr) 2000-01-26

Family

ID=27124996

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98919433A Withdrawn EP0973528A2 (fr) 1997-04-09 1998-04-09 Composition therapeutique, procede de preparation de la composition et utilisation de cette derniere pour traiter des infections virales chez l'homme

Country Status (4)

Country Link
EP (1) EP0973528A2 (fr)
AP (1) AP9901681A0 (fr)
AU (1) AU7229598A (fr)
WO (1) WO1998044935A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102196812B (zh) * 2008-09-03 2013-11-06 株式会社Nbc纱网技术 抗病毒剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01149730A (ja) * 1987-12-07 1989-06-12 Osaka Prefecture レトロウイルス増殖抑制剤
FR2659234B1 (fr) * 1990-03-12 1994-07-01 Fileco Sa Composition therapeutique contenant un compose phenol et de la propolis utile contre les virus a capside lipidique, notamment les virus de l'herpes.
SE501793C2 (sv) * 1993-10-08 1995-05-15 Perstorp Ab Användning av inositoltrisfosfat för beredning av läkemedel
SE502989C2 (sv) * 1993-11-22 1996-03-04 Perstorp Ab Användning av en inositoltrisfosfatester för beredning av läkemedel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9844935A2 *

Also Published As

Publication number Publication date
WO1998044935A2 (fr) 1998-10-15
WO1998044935A3 (fr) 1998-12-30
AP9901681A0 (en) 1999-12-31
AU7229598A (en) 1998-10-30

Similar Documents

Publication Publication Date Title
Aoun et al. The fluoride debate: the pros and cons of fluoridation
CN107373218A (zh) 一种矿物质功能饮料
Waldbott Mass intoxication from accidental overfluoridation of drinking water
JP3131448B2 (ja) 人参加工方法及びそれにより製造される加工人参
Dannenfeldt The introduction of a new sixteenth-century drug: Terra Silesiaca
WO1998044935A2 (fr) Composition therapeutique, procede de preparation de la composition et utilisation de cette derniere pour traiter des infections virales chez l'homme
Callaway et al. Toxic epidermal necrolysis caused by gin and tonic
Edmonds et al. Sodium azide poisoning in five laboratory technicians
JPH0840874A (ja) 浴用入浴剤
EP0372676A1 (fr) Préparation thérapeutique et procédé
JPH05155774A (ja) 月経困難症を緩和する効果のある、 カルシウム利用性に優れた 飲食品及び医薬品
JPS58162526A (ja) ヘルパ−
Norton Experimental therapeutics in the renaissance
Lafontaine et al. Treatment of multidrug-resistant tuberculosis in Russian prisons
JPH08205835A (ja) 健康飲料
KR20130092653A (ko) 숙취해소용 천연차 및 그 제조방법
Kohn A look at iodine-induced hyperthyroidism: Recognition.
RU2227035C1 (ru) Состав для профилактики и лечения фиброзно-кистозной мастопатии
Rubin Prescribing in pregnancy
Weissmann A fashion in metals
AU629520B2 (en) A medicament
Rennie A new supplement to the pharmacopæias of London, Edinburgh, Dublin and Paris
JPH0859488A (ja) 健康増進剤
Osborn ART. VI.--SCAMMONY AND JALAP: IDENTITY OF THEIR ACTIVE PRINCIPLES.
RU2071347C1 (ru) Способ получения лечебно-профилактического напитка

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991108

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 33/34 A, 7A 61K 38/21 B, 7A 61P 31/18 B, 7A 61K 33/34 J, 7A 61K 33:24 J, 7A 61K 33:04 J, 7A 61K 31:05 J, 7A 61K 31:045 J

17Q First examination report despatched

Effective date: 20010912

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040517